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The increasing utilization of hemodialysis for long-term
maintenance in end-stage renal insufficiency has led to the
recognition that hyperparathyroidism and renal osteo-
dystrophy are frequent, if not universal, complications.
Although scattered reports have dealt with factors in-
fluencing the development of these conditions, there has
been little systematic evaluation. Recently, attention has
focused on inorganic phosphate retention and on the
calcium content of the dialysate bath. Since other reports
in this issue of Kidney International will deal with ab-
normalities of vitamin D metabolism, this paper will only
touch on this aspect and will concentrate on calcium (Ca)
and phosphate (P1) per se. An excellent comprehensive
review of the entire subject has been published recently by
Stanbury [1].
Definition of problem
The frequency with which overt renal osteodystrophy
develops during long-term hemodialysis has varied widely
among dialysis centers, from essentially zero [2, 3] to more
than 85% [4]. The criteria for diagnosis of bone disease
have not been uniform, however, and it is not clear how
much of the reported involvement was definitely osteitis
fibrosa and how much was osteomalacia. Kaye [2] has
pointed out that nearly all of his patients had hyperpara-
thyroidism at the time of beginning dialysis therapy, based
on serum values of immunoreactive parathyroid hormone
and bone biopsy, yet only one-quarter showed roentgeno-
graphically detectable disease.
It has been stated [5—7] that in patients on long-term
dialysis the incidence of overt bone disease increases with
duration of therapy. In fact, Massry et al [7] have reported
that the frequency of roentgenographic evidence of osteo-
dystrophy increased progressively from 18% in patients
dialyzed for less than one year to 70 % between one and
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two years, and 92% in those treated longer than two years
when the dialysate contained 5.2 to 5.5 mg of Ca/100 ml.
Our own data fail to show any relationship between bone
disease and duration of either known renal insufficiency or
dialysis therapy [8].
Similar discrepancies have been reported in regard to
the symptoms associated with osteodystrophy. Pendras [6]
reported that bone tenderness and pain were common in
osteitis fibrosa and not in osteomalacia, yet Massry et al
[7] found that bone pain was uncommon in their patients
with hyperparathyroidism. However, both agreed that
vascular and metastatic calcification were frequent features
of renal hyperparathyroidism, and Massry et al also
particularly emphasized the itching and skin calcification.
The foregoing suggests that there must be factors inherent
either in the renal disease peculiar to different localities or
in the dialysis program used in different centers to account
for the differences in bone disease incidence. There seems
to be no reason to suspect the type of renal disease a priori
because, at the time of institution of a dialysis program,
there usually is no renal function of consequence remain-
ing. Furthermore, we have found no demonstrable rela-
tionship between type of renal disease and incidence of
bone disease in our patients [8]. Therefore, we are inclined
to the view that factors inherent in the dialysis program are
likely to be responsible, at least in large measure, for the
development of osteodystrophy.
Until relatively recently, there was essentially no ap-
preciation of the potential importance of dialysis factors
which are amenable to modification. In fact, there was
little recognition that renal osteodystrophy might actually
develop or worsen as a result of dialysis. Therefore, few
efforts were made to alter the composition of the dialysate
bath or to provide sufficient control over its composition
with the goal of preventing such disease. The recognition
that the incidence of bone disease varies widely from center
to center may have been a major factor in changing our
entire conception of the problem.
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Rational approach to therapy
It is necessary to examine briefly the factors generally
considered to be etiologic for renal osteodystrophy in order
to arrive at a rational approach to study. The pathogenetic
sequence, especially in relation to hyperparathyroidism, is
discussed in greater detail in this symposium by Arnaud.
In this interpretation, primacy is given to phosphorus
retention [9—12] and to an abnormality in vitamin D
metabolism [13—17]. An additional factor, which might be
secondary to the vitamin D abnormality, is apparent
skeletal resistance to the action of parathyroid hormone
(PTH) [18, 19]. All of these factors tend to produce a de-
crease in plasma with a consequent increase in
secretion of PTH.
The apparently central role of low plasma ionized
calcium concentration in the pathogenesis both of osteo-
malacia and of osteitis fibrosa suggests that efforts should
be directed specifically at correcting this factor. Because
the active metabolite of vitamin D3, 1,25-(OH)2D3, is not
yet available in large enough amounts for use in extensive
therapeutic trials, our efforts must be aimed at circum-
venting the necessity for its use by increasing the serum
calcium concentration through other modalities. In fact, it
remains questionable as to whether therapy with one or
another active vitamin D metabolite will actually prove to
be the mainstay of early treatment. In view of the extra-
ordinary potency of I ,25-(OH)2D3 in patients with renal
failure [20], it is possible that therapeutic doses might be
dangerously close to doses which would produce hyper-
calcemia in the presence of severe hyperparathyroidism.
Therefore, it might be desirable to decrease parathyroid
hypersecretion to near normal values by other means prior
to administering 1,25-(OH)2D3. This would permit use of
Fig. 2. Factorial study of effects of changing dialysate Ca (DCa)
and plasma P on plasma iPTH. Plasma P1 was decreased by oral
administration of aluminium hydroxide. Plasma iPTH at the
end of the first period was considered as the 100% value. (From
[22] by permission of Dun Donnelley Publishing Corporation.)
much smaller maintenance doses, not approaching toxic
levels, to improve Ca absorption and normalize calcifica-
tion of osteoid. This must remain speculation, however,
until large-scale trials are feasible.
We observed in our patients that plasma concentrations
of immunoreactive PTH (iPTH, measured by antiserum
GP 1 M) [21] were higher in patients with clinical or
roentgenographic evidence of renal osteodystrophy than in
those without, although values were greatly increased in all
patients [21, 22]. Dialysate Ca (Fig. 1) and plasma in-
organic phosphate (P1) concentrations were significantly
correlated with iPTH, respectively negative and positive.
Furthermore, when dialysate Ca and plasma P1 were varied
independently for periods of 2 to 3 weeks in a small series
of patients, significant changes in plasma iPTH occurred
(Fig. 2), with the highest values during the lower dialysate
Ca-higher plasma P1 period and the lowest values during
the higher dialysate Ca-lower plasma P1 period [21, 22].
These observations strongly support the etiologic schema
described by Arnaud and provide a rational basis for a
therapeutic regimen (Table 1) which could be expected to
prevent, or at least reverse, the osteitis fibrosa component
of renal osteodystrophy.
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Mean DCa of previous dialyses, mg/lOO ml
Fig. 1. Relationship of plasma iPTH (antibody GF 1 M) to
dialysate Ca in patients on maintenance hemodialysis. (From [22]
by permission of Dun• Donnelley Publishing Corporation.)
Control of phosphate retention
Certainly one of the first and most important goals must
be to decrease plasma P1. As Pendras [6] has pointed out,
serum P1 in these patients is a direct function of the dietary
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Table 1. Recommended dialysis program
1. Begin dialysis with dialysate Ca concentration of 5 to
6 mg/100 ml
2. Administer aluminum hydroxide or aluminum carbonate
orally in doses sufficient to decrease plasma P1 to <6 mg/
100ml
3. Increase intensity of dialysis (frequency or duration or both)
if necessary to assist in decreasing plasma P1
4. Increase dialysate Ca concentration to 7 to 8 mg/tOO ml
5. Dialyze for 6 hours three times weekly (may vary with type
of dialyzer)
6. Monitor plasma Ca and P1 to determine necessity for adjust-
ment of oral dosage of P1-binding agent in order to avoid
hypophosphatemia
P1 and the activity of osteitis fibrosa and an inverse func-
tion of the intensity of dialysis. The activity of osteitis
fibrosa is presumably related directly to the degree of
hyperparathyroidism, which in turn is dependent on
plasma Ca+ . We must therefore consider increasing the
intensity of dialysis or decreasing the intake of P1. Although
increasing the frequency and duration of dialysis is practi-
cal for short periods, such as at the time of initiating
dialysis therapy, it is not practical for long-term dialysis
because of expense and interference with normal activities.
On the other hand, the ready availability of oral r
binding antacids, such as aluminum hydroxide and
carbonate, provides a rapid method for inhibiting absorp-
tion of P [23—25]. Many patients with renal failure seem
to experience an excessive degree of intolerance to these
binding agents, often with nausea and vomiting. However,
we have found that trial of the various products on the
market usually leads to identification of one or more that
can be tolerated.
Our current experience is that the most frequently
acceptable commercial products are Alucaps ®, 0.5 g (as
aluminum oxide) per capsule (Riker Laboratories),
Amphojel ® tablets, 0.6 g per tablet (Wyeth Laboratories),
and Basaljel ® concentrate, 3.6 g/30 ml (Wyeth Labora-
tories). Basaljel concentrate has the significant advantages
of being virtually tasteless and requiring only small volumes
per dose, thus permitting it to be mixed with various foods
if desired. In some cases, we have prepared gelatin capsules
of the powder or wax-coated tablets for the unusually
refractory patient, with good success [22]. As illustrated in
Fig. 3, it is possible to decrease the plasma P1 with these
agents, and we have found it almost always possible to
decrease the value to 6 mg/I® ml or less with the use of
the aluminum compound.
In some eases we have increased the intensity of dialysis
simultaneously in order to achieve the initial decreases. It
should be emphasized that many of these patients require
careful coaxing and continuous emphasis on the importance
of this facet of treatment in order to accomplish this goal.
When properly managed, P. deprivation may be so sue-
Fig. 3. Plasma iPTH, Ca, and P1 during dialysis against dialysate
Ca of 5.5 and 8.0 mg/100 ml. Plasma P1 was initially decreased
by oral aluminium hydroxide. (From [22] by permission of
Dun Donnelley Publishing Corporation.)
cessful that hypophosphatemia may actually occur, and we
have seen decreases to less than 1 mg/100 ml. This must be
carefully guarded against, since it may lead to significant
worsening of the osteomalacia [21—25]. It is clear, therefore,
that the goal of this therapy is to return plasma P1 to nor-
mal, avoiding both hyperphosphatemia and hypophos-
phatemia.
The recent observations by Slatopolsky et al [11] on the
prevention of hyperparathyroidism in dogs rendered renally
insufficient in stepwise decrements of renal function
provide further documentation of the importance of
relative P1 deprivation. These workers, confirming their
earlier predictions [9, 10], showed that a decrease of P1
intake proportional to the decrease in renal function ef-
fectively prevented an increase in plasma iPTH. These
studies coupled with the data in man appear to document
conclusively the importance of avoiding P retention.
Control of calcium deficiency
It is equally clear from the pathogenetic schema described
by Arnaud, however, that P1 depletion is not enough to
prevent or reverse hyperparathyroidism and dialytic bone
disease because malabsorption of Ca and hypocalcemia
might still remain. Thus, in addition to the P1 problem,
one can view the other major pathogenetic factor as Ca
deficiency due primarily to inadequate synthesis of 1,25-
(OH)2D3 [13—17]. Short of providing sufficient amounts
of exogenous 1,25-(OH)2D3, therapeutic efforts might be
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repletion is in the appropriate range for correction of fecal
losses of Ca during long-term dialysis, which have been
reported to be in the vicinity of 1.5 g/wk [1, 37, 38}.
That there is a true Ca repletion during use of a high
dialysate Ca concentration has recently been confirmed by
studies of total body Ca with the technique of neutron
activation analysis [39}. It was reported that a high dialy-
sate Ca concentration (6.5 mg/100 ml) caused retention of
Ca and loss of P1, whereas a low concentration (5 mg/lOOml)
caused loss of Ca and retention of P1.
Furthermore, none of the patients in our study in-
creased his plasma Ca to more than 11 mg/lOOml with
dialysate Ca of up to 8 mg/100 ml. This points up one of
the advantages to this approach —Ca transfer would
decrease as the Ca gradient decreased due to increasing
plasma Ca. There is thus a built-in control that prevents
excessive hypercalcemia. It is possible that, as the excessive
osteoid is calcified, less of a positive intradialysis Ca
balance would be needed [1]. If this is the case, it might be
desirable to decrease the dialysate Ca to 6 to 7 mg/l00 ml
in order to avoid potential Ca overload. This is purely
speculative; our data to date have indicated no need for
such a decrease.
It has been reported [40] that dialysis against such a high
Ca concentration may cause significant hypercalcemia
(11 to 12 mg/100 ml), an effect not observed in our patients.
It is possible that one of the explanations for this minor
discrepancy is the difference in duration of individual
dialyses. Whereas our dialyses were generally of only
6 hours' duration [21, 22], those reported to have resulted
in excessive increases in plasma Ca were 8 to 10 hours in
duration [40]. Thus, the additional Ca delivered during the
extra 2 to 4 hours may have been sufficient to produce
acute Ca overload, although it seems likely that the decreas-
ing Ca gradient would not permit severe hypercalcemia to
occur. It also is important to recognize that the type of
dialyzer used will have a significant effect on Ca transfer.
As would be anticipated from the slight hypercalcemia
(10 to 11 mg/100 ml) induced recurrently by this dialysis
procedure, plasma iPTH progressively decreases with time
(Fig. 3) [22]. It was of some concern to us that this hyper-
calcemia might lead to metastatic calcification, as has been
suggested in the past [41, 42]. Presumably because of the
prior decrease in plasma P1 and the maintenance of Ca x P,
product less than 70 (Ca < 11, P1 <6), no such complication
has been observed by us. In fact, it was found that, when
present at the initiation of this therapy, metastatic calcifi-
cation did not change significantly. We infer that the
decrease in plasma P1 was a critical factor in this
difference from other studies, in which there usually
was less control of P1. probably because of patient in-
12 tolerance to the aluminum-containing antacids. Massry
et al [42] found that the skin Ca content was significantly
increased during dialysis against a Ca concentration of
8 mg/100 ml. It should be pointed out that plasma P1 was
not successfulJy decreased in their patients, so that the
aimed at circumventing the defect in synthesis by direct
administration of Ca. DeWardener et al [26—28] have
already indicated that this can be accomplished by provid-
ing large oral doses of Ca. Partially because of our obser-
vations [21, 22] on the relationship of dialysate Ca con-
centration to plasma iPTH, we have chosen to pursue the
alternative route of administering Ca via the dialysis. In
addition, we have found it much easier to control plasma
Ca concentration by the dialyses than with oral doses of
calcium carbonate; we occasionally encountered un-
expected hypercalcemia with the oral agent in patients who
had seemed to be stabilized.
Substantial data in the literature point to the role of
dialysate Ca in determining the net transfer of Ca during
dialysis [29—36]. In general, these studies have indicated
that the primary factor influencing Ca transfer is the
gradient between dialysate Ca and the plasma ultra-
filtrable Ca. In recent studies of bidirectional fluxes of Ca
across the mini-Kiil dialyzer, we have also found the
gradient to be of prime importance [22, 34], although other
factors played secondary roles.
Because it may not always be practical to tailor indi-
vidual dialysates to individual patients, we also examined
the relationship between dialysate Ca and flux, without
specific regard to plasma ultrafiltrable Ca. As shown in
Fig. 4, a significant linear relationship was found between
dialysate Ca and net Ca transfer, the only deviations being
two dialyses in one patient who was hypercalcemic. This
figure also illustrates that a dialysate with a Ca concen-
tration below 6 mg/100 ml may actually remove Ca from
the patient, thus aggravating the Ca deficiency and tending
to worsen the hyperparathyroidism. Examination of the
individual dialyses disclosed that mean net transfer of Ca
to the patient was 1.5 mg/mm with a dialysate Ca of
7 to 8 mg/100 ml. During six hours of dialysis, therefore,
the patient would receive in effect a Ca infusion of about
540 mg, thereby repleting the Ca stores. This degree of Ca
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Fig. 4. Mean Ca transfer (mg/mm) during 6-hour dialyses, as a
function of dialysate Ca. (From [221 by permission of DunDon-
nelley Publishing Corporation.)
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Ca x P1 product was presumably higher than in our
patients.
Confirmation of the significance of the decreasing plasma
iPTH was obtained in the form of serial biopsy data and
40 -
30Bone
resorption
% 20
Normal _iP
SD
A 0 24 6 80 24 6 8
Interval between biopsies, months
Fig. 5. Effect of two levels of dialysate Ca concentration on
bone-resorbing surface. (From JowsEY J, JOHNSON WJ, TAVES
DR, KELLY PJ: J Lab Clin Med 79:204—214, 1972, by permis-
sion of The C. V. Mosby Company.)
Fig. 6. Effect of long-term (6 months) dialysis against Ca of
S mg/100 ml and maintenance of plasma P below 6 mg/IOO ml on
subperiosteal resorption. Left, Initial. Right, At 6 months. (From
VOSIK WM, ANDaRSON CF, STEFFEE WP, JOHNSON WJ, AR-
NAUD CD, GOLDSMITH RS: Mayo Clin Proc 47:110—113, 1972,)
skeletal roentgenograms. Both bone resorption surface
(quantitative microradiography) (Fig. 5) and subperiosteal
resorption (Fig. 6) decreased. Whether these effects were
greater with a dialysate Ca of 8 mg/I® ml than with one
of 6 mg/i® ml has not yet been determined, although the
plasma iPTH definitely responded more to the higher
dialysate Ca. Coburn et a! [40] have compared skeletal
changes by quantitative microradiography in patients dia-
lyzed against a bath Ca of either 6.5 or 8 mg/l00 ml and
found no differences. Since control bone biopsies were not
performed prior to initiation of the two dialysis regimens
and since plasma P1 was not well controlled, their studies
are not strictly comparable to our own and will be difficult
to interpret in the context of our proposed regimen.
Increasing the concentration of magnesium (Mg) in the
dialysate as a means of controlling hyperparathyroidism
has recently been suggested by Pletka et al [43]. They
reported that plasma iPTH may be decreased by increasing
the dialysate Mg to 2.5 mEq/liter. Stanbury [1] has sug-
gested that Kaye's observation [2] of a low incidence of
bone disease in his patients might be a result of his having
used a similar dialysate Mg concentration. Mg is thought
to inhibit secretion of PTH in much the same way as Ca
does, so that this approach certainly has merit. It should be
remembered, however, that significant hypermagnesemia
should be avoided because it may be associated with
lethargy, drowsiness, ataxia, hypotension, or cardiac arrest
[44, 45].
Role of parathyroidectomy
In a sense, the proposed regimen (Table 1) may be
viewed as a medical parathyroidectomy. A number of
authors have pointed out the value of surgical para-
thyroidectomy in the control of osteitis fibrosa and meta-
static calcification [1—7, 46]. Because increased secretion
of PTH is such a central factor in the development of
these complications of renal disease, it could be expected
that parathyroidectomy should be a helpful therapeutic
maneuver. However, in our opinion, based in part on the
data described here, it usually is possible to accomplish
much the same end, albeit not so rapidly, by nonsurgical
means.
Nonetheless, there remain indications for surgical para-
thyroidectomy. In our view, such a procedure is indicated
if the patient is severely hypercalcemic, if medical therapy
is unsuccessful in controlling the hyperparathyroidism and
oSteitis fibrosa, or if the dialysate Ca concentration cannot
be increased without inducing severe hypercalcemia. Our
experience indicates that such failures are rare, but the
possibility must be borne in mind.
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